Drugs / Ezurpimtrostat
Ezurpimtrostat
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05353894 | May → Nov 2022 | liver cancer | Genoscience Pharma | Unknown | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05874414 | Aug 2023 → Dec 2027 expected | cholangiocarcinoma | Genfit | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03316222 | Apr 2018 → Jan 2021 | hepatocellular carcinoma, intrahepatic cholangiocarcinoma | Genoscience Pharma | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05448677 | Dec 2022 → Mar 2024 | hepatocellular carcinoma | University Hospital, Grenoble | Terminated | No outcome recorded |
| Phase 2 | NCT04637828 | Nov 2020 → Jul 2021 | COVID-19 | Genoscience Pharma | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ezurpimtrostat | “GNS561/Ezurpimtrostat is a first-in-class, orally bioavailable, small molecule that blocks cancer cell proliferation by inhibiting late-stage autophagy and dose-dependent...” PMID 35949290 ↗ Feb 2022 |
| Known as | Ezurpimtrostat (GNS561) | “Ezurpimtrostat (GNS561)” NCT05874414 ↗ |
| Known as | GNS561 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04637828 ↗ |
| Modality | Small molecule | “a first-in-class, orally bioavailable, small molecule” PMID 35949290 ↗ Feb 2022 |
| Route | Oral | “single oral intake 3 times a week” PMID 35949290 ↗ Feb 2022 |